Supplemental Material: Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa

Published: 7 November 2025| Version 1 | DOI: 10.17632/8bjtsp9cf2.1
Contributors:
Christopher J. Sayed, Brian Kirby, Amit Garg, Haley Naik, Alexa B. Kimball, Christos C. Zouboulis, Gregor B. E. Jemec, Georgios Kokolakis, John Ingram, Akimichi Morita, Delphine Deherder, Christina Crater, Robert L. Rolleri, Tom Vaux, Jérémy Lambert, Bartosz Lukowski, Falk G. Bechara

Description

Supplemental Material for the manuscript titled "Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension", published in the Journal of the American Academy of Dermatology. Contents: Supplementary Methods 1. Prespecified safety topics of interest Supplementary Figure 1: BE HEARD I and II and BE HEARD Extension study design Supplementary Figure 2: Safety pooled data Supplementary Figure 3: Missing data handling Supplementary Figure 4: HiSCR50/75/90/100 over time in BKZ Total patients (mNRI [AE-LoE]) Supplementary Figure 5: Efficacy- and lesion-based outcomes over time in BKZ Total patients (MI [AE-LoE] and mNRI [AE-LoE]) Supplementary Table 1. HiSCR50/75/90/100 to Week 96 in patients receiving BKZ Q2W/Q4W/Q4W (OC)

Files

Categories

Dermatology, Cytokines, Skin Disease, Randomized Clinical Trial, Inflammatory Disorder, Hidradenitis Suppurativa, IL-17A Signaling Pathway

Funders

  • UCB

Licence